Dabigatran versus warfarin in atrial fibrillation: Multicenter experience in Turkey

Aslan O., Yaylali Y., Yildirim S., Yurtdas M., Senol H., Ugur-Yildiz M., ...Daha Fazla

Clinical and Applied Thrombosis/Hemostasis, cilt.22, sa.2, ss.147-152, 2016 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1177/1076029614546327
  • Dergi Adı: Clinical and Applied Thrombosis/Hemostasis
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.147-152
  • Anahtar Kelimeler: drug monitoring, hemorrhage, myocardial infarction, stroke, thromboembolism
  • Çanakkale Onsekiz Mart Üniversitesi Adresli: Hayır

Özet

Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P =.015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P =.104). Death from any cause occurred in 10 (4.6%) patients in the warfarin group versus 1 (1.0%) patient in the 110-mg dabigatran group (P =.005). Dabigatran was associated with less ischemic stroke and death from any cause than warfarin. Dabigatran may be a better option for stroke prophylaxis, where recommended monitoring with warfarin is suboptimal.